Clinical trials
catalyst calendar across sponsors →Studies where VERA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 13 tracked-famous managers (Qube Research & Technologies Ltd, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +8 more) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptNCT06674577Incidence of adverse events observed during the dosing periodOpen-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Atacicept 150 mg | IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease | 750 | 2031-05-21 | in 1,736 d | 2026-06-22 |
| Atacicept in Multiple Glomerular DiseasesNCT06983028AE profile and results of routine clinical and laboratory testsNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Atacicept | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | 250 | Nov 2027 | ≤ 468 d | 2026-06-26 |
| Monthly Dosing of Atacicept in IgANNCT07020923Evaluate the effect of atacicept on Gd-IgA1 in patients with IgANRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Atacicept | IgA Nephropathy (IgAN), Berger Disease | 90 | Sep 2026 | ≤ 42 d | 2026-04-13 |
| Atacicept in Subjects With IgA NephropathyNCT04716231Change from baseline in urine protein to creatinine ratio (UPCR)Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Atacicept · Other: Placebo to match Atacicept | IgA Nephropathy, Berger Disease | 376 | 2025-05-15actual | — | 2025-09-30 |
| Atacicept in Subjects With Active Lupus Nephritis (COMPASS)NCT05609812Renal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%Randomized · Double-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns. | Drug: Atacicept, Placebo | Lupus Nephritis (LN) | 0 | 2026-03-15 | — | 2025-05-23 |
| A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant RecipientsNCT04294472results2023-05-24Time (Weeks) to Decrease of BKV Plasma Viral Load by 1 LogRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MAU868 · Other: Placebo | BK Virus Infection | 30 | 2022-02-10actual | — | 2023-06-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19